country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P991455

Copy Link Print Information

Biologically Validated

PTX-35

Kundenbewertung

Based on 1 Customer Validation

PTX-35 is a costimulatory agonist antibody targeting TNFRSF25 as well as an immune activator that selectively regulates activated CD8⁺ T cells. PTX-35 enhances the expansion, survival and effector functions of T cells, while reducing the inhibitory activity of regulatory T cells and impairing their stability. PTX-35 exhibits anti-tumor activity, effectively delaying tumor progression and prolonging survival. PTX-35 has a synergistic effect with anti-OX40 agonist antibodies. PTX-35 can be widely used in research on related diseases such as colon cancer and melanoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.95%
Molecular Weight:145.58 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

PTX-35 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Anwendung
- Verified Bioactivity
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG1 lambda2

Recommend Isotype Controls

Human IgG1 lambda2, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

TNFRSF25

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

In Vivo

Mouse PTX-35 (mPTX-35) , in the presence of tumor antigens, reprograms the Treg cell phenotype by reducing Treg suppressive activity and increasing Treg plasticity toward inflammatory Th1 and Th17 cells, which is associated with delayed tumor progression in a murine melanoma model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

8718 [NCBI]

Accession

Q93038

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized Human-DR3-his can bind PTX-35. The EC₅₀ for this effect is 69.63 ng/mL.

Chemical Information

Appearance Liquid
Molecular Weight 145.58 kDa
Color Colorless to light yellow
SMILES

[3H][P][F,Cl,Br,I]
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (258 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Tahiliani V, et al. Abstract 2224A: A novel TNFRSF25 agonist, PTX35, synergizes with Gp96-Ig/OX40L-Ig to enhance effector and memory anti-tumor CD8+ T cell responses and delay tumor growth[J]. Cancer Research, 2020, 80(16_Supplement): 2224A-2224A.

[2]. Kalim K W, et al. PTX-35, a potential first-in-class TNFRSF25 agonist, reduced the suppressive activity of regulatory T cells and enhanced CD4+ T cell effector responses, in the presence of tumor antigens, in a murine melanoma model[J]. Cancer Research, 2021, 81(13_Supplement): 604-604.

[3]. Simons F E R. Advances in H1-antihistamines[J]. New England Journal of Medicine, 2004, 351(21): 2203-2217.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Anwendung
- Biological Activity
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PTX-35

Cytotoxicity LDH Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Antibody Inhibitor Library

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

PTX-35 Related Classifications

HY-P991455 Related Classifications